Board of Directors

Meet our Board of Directors.

Providing expert guidance and strategic insight to help us fulfill our mission to discover, develop and commercialize life changing therapies for children and adults affected by CNS disorders and rare diseases.

Scott Braunstein, M.D., Director

Scott Braunstein, MD has served on our board since September 2018. Dr. Braunstein brings over 20 years of knowledge and experience from diverse biotechnology and pharmaceutical industry vantage points. Dr. Braunstein is currently an operating partner at Aisling Capital. He most recently served as chief operating officer at Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. Prior to Pacira, Scott served as a healthcare portfolio manager at Everpoint Asset Management and spent 12 years with J.P. Morgan Asset Management as a healthcare analyst and managing director in the U.S. Equity team, and as a portfolio manager in the Global Healthcare team responsible for managing investments in pharmaceuticals, biotechnology, and medical devices. Dr. Braunstein is currently on the board of directors at Esperion Therapeutics and serves as chairman at ArTara Therapeutics. Scott began his career as a practicing physician at the Summit Medical Group and as assistant clinical professor at Albert Einstein College of Medicine and Columbia University Medical Center. He earned his medical degree from the Albert Einstein College of Medicine.


Christopher M. Cashman, Chairman of the Board and Chief Executive Officer

Chris is a recognized leader in the life sciences industry with nearly 40 years of proven executive management experience in developing and commercializing new medicines targeting diverse diseases. Under Chris’s leadership, Marinus has advanced the development of ganaxolone into pivotal studies in rare, genetic epilepsies and is conducting proof-of-concept studies in postpartum depression. Chris is a seasoned CEO, having previously served as President and CEO of two private biotech companies, Protez Pharmaceuticals, Inc., and Message Pharmaceuticals, Inc., both of which were acquired by other life science companies. Chris spent the first twenty-five years of his career at SmithKline Beecham plc (acquired by GlaxoSmithKline) and Pfizer where he held various executive leadership positions including vice president of animal health and global director of new product development. During his tenure, he oversaw the commercial, sales and marketing teams and led new product development collaborating with research and clinical development teams.

Chris is currently a member of the Boards of Directors of Life Sciences Pennsylvania, the Science Center, Rapid Micro Biosystems, Inc., Noble Biomaterials, Inc., and MBF Therapeutics, Inc. Chris holds an M.S. in economics from Purdue University and B.S. in business management from the University of Minnesota.


Enrique J. Carrazana, M.D., Director

Enrique J. Carrazana, M.D., has served on our Board since November 2013. Dr. Carrazana is the former Chief Medical Officer of Acorda Therapeutics, Inc., where he was responsible for the management of drug development programs and regulatory filings, as well as the company’s medical affairs and drug safety departments. Previously, Dr. Carrazana held various medical leadership roles at Novartis, where his last role was Vice President, Global Head Development Established Medicines Franchise based in Basel, Switzerland. He was also Director of the Epilepsy Center of Excellence at the Miami Veterans’ Administration (VA) Hospital and Associate Professor of Neurology at the University of Miami Miller School of Medicine. Dr. Carrazana is a board-certified neurologist with more than 20 years of experience in the pharmaceutical industry and clinical practice. He has presented and published a wide range of research on various neurology topics, with an emphasis on epilepsy. Dr. Carrazana received his medical degree from the Harvard Medical School and completed his residency in neurology and fellowship in neurophysiology at the Harvard Longwood Neurology Program.


Michael R. Dougherty, Director

Michael R. Dougherty has served on the Board since February 2017. Mr. Dougherty has over 30 years of experience in the biopharmaceutical industry, most recently serving as executive chairman of Celator Pharmaceuticals, Inc. Prior to Celator, Mr. Dougherty was chief executive officer and a member of the board of directors of Kalidex Pharmaceuticals, Inc. Mr. Dougherty also served in a number of capacities during his ten-year tenure at Adolor Corporation, including president and chief executive officer, member of the board of directors, senior vice president of commercial, chief operating officer, and chief financial officer. Prior to Adolor, Mr. Dougherty was president and chief operating officer of Genomics Collaborative, Inc. and served in a variety of senior positions at Genaera Corporation, including president and chief executive officer, and at Centocor, Inc. Mr. Dougherty is currently on the board of directors at Trevena, Inc. and Aviragen Therapeutics. Mr. Dougherty received a bachelor’s degree from Villanova University.


Seth H.Z. Fischer, Director

Seth H.Z. Fischer has served on our Board since September 2016. Mr. Fischer currently serves as a member of the Boards of Directors of Agile Therapeutics, Inc. and BioSig Technologies, Inc., and as strategic advisor to VIVUS, Inc and MedHab, LLC. Prior to this Mr. Fischer served as CEO and Director to VIVUS, Inc., a publicly traded biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity and sexual health. Prior to VIVUS, Mr. Fischer served in various positions at Johnson & Johnson, most recently as Company Group Chairman, Johnson & Johnson and Worldwide Franchise Chairman of Cordis Corporation. Prior to that he served as Company Group Chairman, North America Pharmaceuticals, which included responsibilities for Ortho-McNeil Pharmaceuticals, Janssen and Scios and prior to that, Mr. Fischer served as President of Ortho-McNeil Pharmaceuticals. Mr. Fischer’s operating responsibilities encompassed the commercialization of products in multiple therapeutic categories including Topamax® for epilepsy and migraines and products in the neurologic, analgesic, anti-infective, cardiovascular, psychiatric and women’s health areas. Mr. Fischer earned a bachelor’s degree in general studies from Ohio University and served as a captain in the U.S. Air Force.


Tim M. Mayleben, Director

Tim M. Mayleben has served on our Board since December 2008. Mr. Mayleben currently serves as President, CEO, and a director of Esperion Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of elevated levels of LDL-cholesterol. Mr. Mayleben has more than a decade of executive leadership roles in the life sciences industry, including former President, CEO and a director of Aastrom Biosciences, Inc., former President, COO and a director of NightHawk Radiology Holdings, Inc., and former COO and CFO of the original Esperion, Inc., until its acquisition by Pfizer in 2004. He is also an advisor to, investor in, and member of the board of directors of several life science companies, including Kaleo, Inc. and LOXO Oncology, Inc. Mr. Mayleben earned an MBA, with distinction, from the J.L. Kellogg Graduate School of Management at Northwestern University, and a BBA from the University of Michigan, Ross School of Business.


Nicole Vitullo, Director

Nicole Vitullo has served on our Board since September 2005. Ms. Vitullo is a Partner at Domain and has extensive experience in both public and private investing in biotech companies and liquidation/distribution strategies for public companies. For more than a decade, Ms. Vitullo was responsible for Domain Public Equity Partners L.P., a fund focused on private investments in public companies. Previous to Domain, Nicole was senior vice president at Rothschild Asset Management, Inc., where she had responsibility for the U.S. public market investments of International Biotechnology Trust plc and Biotechnology Investments Limited. Prior to that, Ms. Vitullo served as the director of corporate communications and investor relations at Cephalon, a publicly traded biotechnology company, and held a number of positions at Eastman Kodak, including corporate development. Ms. Vitullo’s current board memberships include Achillion Pharmaceuticals, Celtaxsys, Inc., Cotera, Inc., Esperion Therapeutics and VentiRx Pharmaceuticals (sold to Celgene, Inc.). Previously, Ms. Vitullo served on the board of Celator Pharmaceuticals (sold to Jazz Pharmaceuticals). Ms. Vitullo received her bachelor’s degree in mathematics and her MBA in finance from University of Rochester.

patient resources

Explore Patient Resources

Find helpful information and patient networks, as well as clinical trial opportunities.

View Patient Resources

join marinus team

Join the Marinus Team

Learn how you can become part of our mission to advance mindful innovation.

Visit Careers Center